

## Coronary Artery Disease Research Studies

The cardiologist at the Main Line Health Heart Center have a long history of participation in clinical trials evaluating novel pharmaceutical agents for the treatment of patients with unstable coronary syndromes both prior to and during cardiac catheterization, evaluation new techniques for successful treatment of coronary Stenosis and evaluating new devices and agents to enhance protection and salvage the ischemic myocardium (damaged heart muscle) in patients.

Patients undergoing heart catheterization and coronary intervention may be candidates for clinical trials involving the latest technology or drug therapies. Our cardiologist and cardiothoracic surgeons will evaluate each patient thoroughly and provide the optimal treatment best suited for them.

<b>Indication</b>	Coronary Artery Disease
<b>Study Title</b>	Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°® Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions - <b>ORBIT II</b>
<b>Sponsor</b>	Cardiovascular Systems Inc.
<b>Purpose</b>	This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely <b>calcified coronary lesions</b> in adult subjects. Study is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety endpoint is 30-day MACE and primary efficacy endpoint is procedural success. All subjects will be treated with the orbital atherectomy system and adjunctive stent. All subjects will be followed in clinic at 30 days. Additionally, all subjects will have an annual phone call or clinical follow up at each anniversary until study is closed.

<b>Indication</b>	ST Elevation Myocardial Infarction (STEMI) and Non-ST Elevation Myocardial Infarction (NSTEMI)
<b>Study Title</b>	<u>T</u> reatment with <u>A</u> DP receptor <u>i</u> nhibitor <u>S</u> : <u>L</u> ongitudinal <u>A</u> ssessment of <u>T</u> reatment Patterns and <u>E</u> vents after <u>A</u> cute <u>C</u> oronary <u>S</u> ndrome : <b>The TRANSLATE-ACS Study</b>
<b>Sponsor</b>	Duke Clinical Research Institute
<b>Purpose</b>	The primary purpose of this observational study in NSTEMI or STEMI patients managed with PCI and initiated on ADP receptor inhibitor therapy are to: <ol style="list-style-type: none"> <li>1. Compare prasugrel to other ADP receptor inhibitor therapy on associated MACE defined as a composite</li> </ol>

	<p>of all-cause death, MI, stroke, or unplanned coronary revascularization through 12 months</p> <p>2. Determine factors associated with initial ADP receptor inhibitor selection at enrollment and longitudinal patterns of use through 12 months</p>
--	--

<b>Indication</b>	New <b>Chest Pain</b> Presentation
<b>Study Title</b>	PROspective Multicenter Imaging Study for Evaluation of Chest Pain - <b>PROMISE</b>
<b>Sponsor</b>	National Heart, Lung and Blood Institute
<b>Purpose</b>	The objective of this NHLBI study is to determine whether an initial non-invasive anatomic <b>imaging</b> strategy with coronary CT angiography (CTA) versus an initial functional testing strategy of exercise or chemical stress test will improve clinical outcomes in subjects with symptoms concerning for coronary artery disease.

For additional information on these studies and other clinical trials, contact the Main Line Health Heart Center at 484-476-3030 or

Lynn Sher, MBA	484-476-8581
Cathy Pensyl, RN, PA-C	484-337-8641
Kim Mayhew, PA-C	484-337-8490
Susan Herring, MEd, RN	484-476-8514